188 related articles for article (PubMed ID: 26819748)
21. Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.
Kavanaugh A; Lee SJ; Curtis JR; Greenberg JD; Kremer JM; Soto L; Etzel CJ; Cox V; Yoshida K; Reed GW; Solomon DH
Ann Rheum Dis; 2015 Jun; 74(6):1150-5. PubMed ID: 25471471
[TBL] [Abstract][Full Text] [Related]
22. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study.
Gossec L; Siebert S; Bergmans P; de Vlam K; Gremese E; Joven-Ibáñez B; Korotaeva TV; Lavie F; Noël W; Nurmohamed MT; Sfikakis PP; Theander E; Smolen JS
Ann Rheum Dis; 2022 Jun; 81(6):823-830. PubMed ID: 35210262
[TBL] [Abstract][Full Text] [Related]
23. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
[TBL] [Abstract][Full Text] [Related]
24. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
[TBL] [Abstract][Full Text] [Related]
25. Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort.
Gremese E; Ciccia F; Selmi C; Cuomo G; Foti R; Matucci-Cerinic M; Conti F; Fusaro E; Guggino G; Iannone F; Delle Sedie A; Perricone R; Idolazzi L; Moscato P; Theander E; Noël W; Bergmans P; Marelli S; Gossec L; Smolen JS;
Clin Exp Rheumatol; 2023 Mar; 41(3):735-743. PubMed ID: 36226614
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
27. The beneficial effect of csDMARDs co-medication on drug persistence of first-line TNF inhibitor in rheumatoid arthritis patients: data from Czech ATTRA registry.
Skácelová M; Nekvindová L; Mann H; Závada J; Křístková Z; Vencovský J; Pavelka K; Horák P;
Rheumatol Int; 2022 May; 42(5):803-814. PubMed ID: 35338383
[TBL] [Abstract][Full Text] [Related]
28. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
29. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
[TBL] [Abstract][Full Text] [Related]
30. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.
Fagerli KM; Kearsley-Fleet L; Watson KD; Packham J; Contributors Group BR; Symmons DPM; Hyrich KL
RMD Open; 2018; 4(1):e000596. PubMed ID: 29479475
[TBL] [Abstract][Full Text] [Related]
31. Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis.
Reed GW; Gerber RA; Shan Y; Takiya L; Dandreo KJ; Gruben D; Kremer J; Wallenstein G
Rheumatol Ther; 2019 Nov; 6(4):573-86. PubMed ID: 31707603
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Young P; Fallon L; Mundayat R; Dina O; Blachley T; Middaugh N; Ogdie A
Rheumatol Ther; 2024 Apr; 11(2):313-329. PubMed ID: 38252211
[TBL] [Abstract][Full Text] [Related]
33. Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.
Mease PJ; van der Heijde D; Karki C; Liu M; Park Y; Greenberg JD
Rheumatol Ther; 2018 Dec; 5(2):537-550. PubMed ID: 30353387
[TBL] [Abstract][Full Text] [Related]
34. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
[TBL] [Abstract][Full Text] [Related]
35. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
[TBL] [Abstract][Full Text] [Related]
36. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
37. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
38. Comparative Effectiveness of First-Line Baricitinib in Patients With Rheumatoid Arthritis in the Australian OPAL Data Set.
Ciciriello S; Littlejohn G; Treuer T; Gibson KA; Haladyj E; Youssef P; Bird P; O'Sullivan C; Smith T; Deakin CT;
ACR Open Rheumatol; 2023 Jul; 5(7):345-353. PubMed ID: 37308464
[TBL] [Abstract][Full Text] [Related]
39. TNFi Cycling Versus Changing Mechanism of Action in TNFi-Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study.
Curtis JR; Kremer JM; Reed G; John AK; Pappas DA
ACR Open Rheumatol; 2022 Jan; 4(1):65-73. PubMed ID: 34741435
[TBL] [Abstract][Full Text] [Related]
40. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
